21. PC.01.6 HUMAN DUODENAL SUBMUCOSAL GLANDS CONTAIN STEM CELLS WITH POTENTIAL FOR LIVER AND PANCREATIC FATES. (25th March 2019) Authors: Cardinale, V.; Carpino, G.; Safarikia, S.; Overi, D.; Costantini, D.; Lu, W. Wei; Riccioni, O.; Nevi, L.; Zhang, W.; Melandro, F.; Zizzari, I.; Moretti, M.; Nuti, M.; Maroder, M.; Berloco, P.B.; Forbes, S.; Reid, L.; Gaudio, E.; Alvaro, D. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 2 Page Start: e73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Arribas, A.; Rinaldi, A.; Spriano, F.; Tarantelli, C.; Gaudio, E.; Bernasconi, E.; Hillmann, P.; Kwee, I.; Stathis, A.; Fabbro, D.; Stüssi, G.; Zucca, E.; Rossi, D.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy. Issue 1 (February 2018) Authors: Carbone, M.; Nardi, A.; Carpino, G.; Cardinale, V.; Ainsworth, H.; Heneghan, M.; Thorburn, D.; Bathgate, A.; Jones, R.; Neuberger, J.M.; Battezzati, P.M.; Zuin, M.; Taylor-Robinson, S.; Donato, M.; Kirby, J.; Mitchell-Thain, R.; Floreani, A.; Sampaziotis, F.; Muratori, L.; Alvaro, D. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. (October 2020) Authors: Arribas, A.; Napoli, S.; Cascione, L.; Gaudio, E.; Bordone-Pittau, R.; Barreca, M.; Sartori, G.; Chiara, T.; Spriano, F.; Rinaldi, A.; Stathis, A.; Stussi, G.; Rossi, D.; Emanuele, Z.; Bertoni, F. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Spriano, F.; Gaudio, E.; Tarantelli, C.; Golino, G.; Cascione, L.; Zucca, E.; Stathis, A.; Giles, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. Specific human cholangiocarcinoma (CCA) subpopulations of cancer stem cells (CSCs) express DoubleCortin-Like Kinase 1 (DCLK1) and DCLK1 inhibition induces anti-cancer effects. Issue 1 (February 2018) Authors: Nevi, L.; Di Matteo, S.; Carpino, G.; Cardinale, V.; Zizzari, I.; Ambrosino, V.; Costantini, D.; Safarikia, S.; Manzi, E.; Derose, A.M.; Melandro, F.; Bragazzi, M.C.; Grazi, G.; Berloco, P.B.; Giuliante, F.; Gaudio, E.; Alvaro, D. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. The anti-CD205 antibody drug conjugate MEN1309/OBT076 shows synergistic activity in combination with the monoclonal antibody rituximab in diffuse large B cell lymphomas. (October 2022) Authors: Tarantelli, C.; Civanelli, E.; Gaudio, E.; Stathis, A.; Merlino, G.; Binaschi, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. (12th June 2019) Authors: Tarantelli, C.; Spriano, F.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 129 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES. (12th June 2019) Authors: Spriano, F.; Tarantelli, C.; Golino, G.; Gaudio, E.; Scalise, L.; Cascione, L.; Zucca, E.; Van Berkel, P.; Stathis, A.; Zammarchi, F.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Bernasconi, E.; Gaudio, E.; Lejeune, P.; Tarantelli, C.; Rinaldi, A.; Kwee, I.; Mensah, A.A.; Chung, E.Y.L.; Stathis, A.; Ocker, M.; Zucca, E.; Haendler, B.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗